Intellia Therapeutics Inc. (NTLA)
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $1.34 per share a year ago.
Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z October 27, 2025 8:30 AM EDT Company Participants Jason Fredette John Leonard - President, CEO & Director David Lebwohl - Executive VP & Chief Medical Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Lili Nsongo - Leerink Partners LLC, Research Division Joseph Thome - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division William Pickering - Sanford C. Bernstein & Co., LLC.
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concerns in ATTR-CM seemed to be resolved quickly, and robust patient demand in pivotal trials support confidence in upcoming Phase 3 data and commercial launches. Cash runway extends into late 2026, but pivotal 2025 catalysts and potential blockbuster approval in multi-billion dollar markets could drive significant upside.
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Brittany Chaves - Corporate Participant David Lebwohl - Executive VP & Chief Medical Officer Edward J. Dulac - Executive Vice President, Chief Financial Officer and Treasurer John M.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $1.31 per share a year ago.
